Business Context and Reporting Period
Company: Myomo, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: February 11, 2020
Event: Entry into a Material Definitive Agreement for a public offering of common stock and warrants.
Key Financial Metrics and Transaction Details
This filing details a capital raise rather than operational financial results. Key transaction metrics include:
- Shares Offered: 2,143,000 shares of Common Stock (or Pre-Funded Warrants) plus Investor Warrants to purchase an equal number of shares.
- Public Offering Price: $7.00 per share of Common Stock and accompanying Investor Warrant.
- Underwriter Purchase Price: $6.5100 per share (representing a 7.0% discount).
- Expected Net Proceeds: Approximately $13.7 million (after underwriting discounts and transaction expenses).
- Over-Allotment Option: Underwriters granted a 45-day option to purchase up to an additional 321,450 shares/warrants.
- Underwriter Warrant: Issued to the representative to purchase 214,300 shares (or 246,445 if over-allotment is exercised) at an exercise price of $7.00.
Operational Financials: The filing text does not provide a clear value for revenue, profit, cash flow, margins, or existing debt levels.
Material Changes and Warrant Adjustments
Warrant Price Adjustment (Item 8.01): The issuance of the new offering at $7.00 per share triggered a significant adjustment to the company's outstanding "2017 Warrants."
- Previous Exercise Price: $42.00 per share.
- New Exercise Price: Reduced to $0.0001 per share.
- Impact: This adjustment effectively makes the 2017 Warrants immediately exercisable at a nominal cost, significantly increasing potential dilution.
Guidance, Outlook, and Risks
Transaction Timeline: The Offering is expected to close on February 13, 2020, subject to customary closing conditions.
Lock-Up Period: The Company agreed not to offer, issue, or sell any shares of Common Stock or convertible securities for 90 days following the Offering without the underwriters' consent.
Warrant Terms:
- Investor Warrants: Exercisable immediately, expire in five years, exercise price of $7.50 per share. Includes a cashless exercise provision in the event of a sale of the Company.
- Pre-Funded Warrants: Immediately exercisable with a nominal exercise price of $0.0001.
Risks: The filing notes that the Underwriting Agreement contains customary representations and warranties made solely for the benefit of the parties and may be subject to limitations. The significant reduction in the exercise price of the 2017 Warrants represents a material dilution risk to existing shareholders.
Key Facts for Investor Verification
- Verify the final closing date and actual net proceeds received, as the $13.7 million figure is an estimate assuming no exercise of Investor Warrants.
- Confirm the total number of outstanding shares post-offering to assess the immediate dilution impact.
- Review the full terms of the 2017 Warrants to understand the implications of the exercise price reduction to $0.0001.
- Monitor the exercise of the 45-day over-allotment option by the underwriters.
- Check subsequent filings for the company's cash position and burn rate to determine how long the $13.7 million in proceeds will sustain operations.